To include your compound in the COVID-19 Resource Center, submit it here.

Grifols' AMBAR approach slows disease progression in moderate Alzheimer’s

Grifols S.A. (Madrid:GRF; NASDAQ:GRFS) reported Phase IIb/III data on its AMBAR approach to treat Alzheimer’s disease demonstrating evidence of mechanism and improvements in clinical outcomes.

AMBAR, which stands for Alzheimer Management by

Read the full 311 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE